AletheiaHQ
Sign In
DIR-E8-CYH-SYM5/LVL 5·Leveraged OperationsHigh-leverage, capital-intensive cell operations. Requires fronted capital or established legal infrastructure. Examples: fronting $10k to lease warehouse space ahead of a known logistics fracture; forming a joint entity to secure and sub-license a dormant government patent for recurring royalties./85% confidence
Return to Directory

Capture SBIR Phase II Success Premium via Predictive Biotech Intelligence Database

Organization
National Science Foundation SBIR program structure that funds technical feasibility but provides zero strategic guidance on follow-on funding success
Sector
SBIR Phase I-funded biotech companies facing 6-month deadline to secure Phase II survival funding
Location
Carlsbad, CA

Source Reference

https://www.nsf.gov/awardsearch/showAward?AWD_ID=2538091

// Venture Capital// Biotech// Database Management// Data Scraping// Machine Learning & Modeling// IP// Open-Source Intelligence// Data Engineering & Pipelines

Executive Context

NSF awarded $305,000 SBIR Phase I funding to ENDURE BIOTHERAPEUTICS for a PKU microbiome therapeutic platform, creating a 6-month window where the company must prove technical feasibility but lacks strategic guidance, vendor intelligence, and IP protection for the critical Phase II transition required for survival.

Catalyst / Timing

ENDURE has $305k with 6-month expiration but lacks the data-driven intelligence to maximize their Phase II success probability. The SBIR system provides capital but no strategic guidance on which vendor choices, investor targets, or competitive positioning will secure the critical $2M+ Phase II follow-on funding required for survival.

Projected Yield

$25,000 per engagement × 10 similar SBIR Phase I biotechs/year = $250k annual recurring revenue

Structural Friction

• Vulnerability: ENDURE has $305k with 6-month expiration but lacks the data-driven intelligence to maximize their Phase II success probability. The SBIR system provides capital but no strategic guidance on which vendor choices, investor targets, or competitive positioning will secure the critical $2M+ Phase II follow-on funding required for survival. • Capital yield: $25,000 per engagement × 10 similar SBIR Phase I biotechs/year = $250k annual recurring revenue • Resource capture: Proprietary database of 500+ SBIR biotech funding outcomes with predictive correlations • Influence capture: First-mover authority in SBIR Phase I-to-II transition intelligence for microbiome therapeutics • Sovereignty yield: Exclusive data moat on what actually drives SBIR Phase II success in specific therapeutic verticals • Required vectors: Vector: Financial Intelligence Analysis, Vector: Data Science & Predictive Modeling, Vector: Biotech Regulatory Knowledge, Vector: Business Development & Sales

Required Capabilities

  • Vector: Financial Intelligence Analysis

    Primary executor: Phase 1: Financial Intelligence Recon: Search SEC EDGAR database for Form D filings by ENDURE BIOTHERAPEUTICS, INC. to i

  • Vector: Data Science & Predictive Modeling

    Supporting vector for: Capture SBIR Phase II Success Premium via Predictive Biotech Intelligence Databa

  • Vector: Biotech Regulatory Knowledge

    Supporting vector for: Capture SBIR Phase II Success Premium via Predictive Biotech Intelligence Databa

  • Vector: Business Development & Sales

    Supporting vector for: Capture SBIR Phase II Success Premium via Predictive Biotech Intelligence Databa

Execution Protocol

Execution Protocol Locked

A one-time payment of $1799 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.

This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.